Mitch P. Levesque

1.1k total citations
9 papers, 169 citations indexed

About

Mitch P. Levesque is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Mitch P. Levesque has authored 9 papers receiving a total of 169 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Oncology and 2 papers in Immunology. Recurrent topics in Mitch P. Levesque's work include Melanoma and MAPK Pathways (5 papers), CAR-T cell therapy research (2 papers) and Peptidase Inhibition and Analysis (2 papers). Mitch P. Levesque is often cited by papers focused on Melanoma and MAPK Pathways (5 papers), CAR-T cell therapy research (2 papers) and Peptidase Inhibition and Analysis (2 papers). Mitch P. Levesque collaborates with scholars based in Switzerland, United States and Germany. Mitch P. Levesque's co-authors include Reinhard Dummer, Phil F. Cheng, Stefan G. Stark, Charlotte Bunne, Andreas Krause, Gabriele Gut, Gunnar Rätsch, Kjong-Van Lehmann, Jacobo Sarabia del Castillo and Lucas Pelkmans and has published in prestigious journals such as Nature Methods, Cancer Research and Cancer Discovery.

In The Last Decade

Mitch P. Levesque

9 papers receiving 169 citations

Peers

Countries citing papers authored by Mitch P. Levesque

Since Specialization

Citations

This map shows the geographic impact of Mitch P. Levesque's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitch P. Levesque with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitch P. Levesque more than expected).

Fields of papers citing papers by Mitch P. Levesque

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitch P. Levesque. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitch P. Levesque. The network helps show where Mitch P. Levesque may publish in the future.

Co-authorship network of co-authors of Mitch P. Levesque

This figure shows the co-authorship network connecting the top 25 collaborators of Mitch P. Levesque. A scholar is included among the top collaborators of Mitch P. Levesque based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitch P. Levesque. Mitch P. Levesque is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Learning single-cell perturbation responses using neural optimal transport 2023 ·Nature Methods ·Charlotte Bunne, Stefan G. Stark, Gabriele Gut, Jacobo Sarabia del Castillo, Mitch P. Levesque, Kjong-Van Lehmann, Lucas Pelkmans, Andreas Krause, Gunnar Rätsch	56
2	Abstract 1301: Evolution of heterogenous BRAFi/MEKi+CDK4/6i resistance mechanisms and targeting site-specific resistant populations in metastatic cutaneous melanoma 2023 ·Cancer Research ·(unknown), Timothy J. Purwin, Claudia Capparelli, Phil F. Cheng, Mitch P. Levesque, Reinhard Dummer, Jessica L.F. Teh, Andrew E. Aplin	1
3	Abstract 1733: MP0317, a CD40xFAP targeting multi-specific DARPin® therapeutic, drives immune activation and reverts myeloid-mediated T-cell suppression in vitro and ex vivo 2021 ·Cancer Research ·Kyriaki Ioannou, Simone Ragusa, (unknown), Ana Florescu, Mariam Gachechiladze, Eliane J. Müller, Julia M. Martínez-Gómez, (unknown), (unknown), Nicolò Rigamonti, (unknown), (unknown), (unknown), (unknown), Anne Goubier, Philippe Legenne, Vladimir Kirkin, Mitch P. Levesque, Hong Ji, Rupert Kenefeck	1
4	Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors 2020 ·Cancer Immunology Research ·Jessica L.F. Teh, Dan A. Erkes, Phil F. Cheng, Manoela Tiago, Nicole A. Wilski, Conroy O. Field, Inna Chervoneva, Mitch P. Levesque, Xiaowei Xu, Reinhard Dummer, Andrew E. Aplin	13
5	Osteoblasts contribute to a protective niche that supports melanoma cell proliferation and survival 2019 ·Pigment Cell & Melanoma Research ·Jennifer Ferguson, (unknown), (unknown), Andrew P. Badrock, Mitch P. Levesque, Reinhard Dummer, Claudia Wellbrock, Michael P. Smith	7
6	In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms 2018 ·Cancer Discovery ·Jessica L.F. Teh, Phil F. Cheng, Timothy J. Purwin, Neda Nikbakht, Prem Patel, Inna Chervoneva, Adam Ertel, Paolo Fortina, (unknown), Kim HooKim, Michael A. Davies, Lawrence N. Kwong, Mitch P. Levesque, Reinhard Dummer, Andrew E. Aplin	61
7	A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma 2018 ·Neoplasia ·L. Krähenbühl, Simone M. Goldinger, Joanna Mangana, Katrin Kerl, Inès Chevolet, Liève Brochez, Christine E. Horak, Mitch P. Levesque, Reinhard Dummer, Phil F. Cheng	26
8	Abstract 1905: Possible cancer stem cells: Folate hydrolase-1 is expressed in a subset of Oct4-positive melanoma cells 2017 ·Cancer Research ·Marigdalia K. Ramirez‐Fort, He Liu, (unknown), Barbara Meier, Mitch P. Levesque, (unknown), (unknown), Emmanuel Contassot, Sae Kim, (unknown), Michael Zhang, (unknown), Paul J. Christos, Scott T. Tagawa, Neil H. Bander, Christopher S. Lange, Lars E. French	1
9	Critical aspects to achieve a high-quality melanoma clinic 2016 ·Current Opinion in Oncology ·Reinhard Dummer, Egle Ramelyte, Mitch P. Levesque, Simone M. Goldinger, Ralph P. Braun	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact